🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Oxycodone/Naltrexone Capsules

    ELITE PHARMACEUTICALS INC /NV/

    Withdrawal Symptoms

    phase 3 small molecule completed

    1 trial

  2. Oxymetazoline Hydrochloride

    Teva Pharma GmbH

    Rosacea

    phase 3 small molecule completed

    1 trial

  3. P1101

    PharmaEssentia

    Polycythemia Vera (PV)

    phase 3 small molecule completed

    1 trial

  4. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  5. PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  6. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  7. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Lacuna Pharma Pty Ltd

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  8. PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Jazz Pharmaceuticals Ireland Limited

    BTC - Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  9. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  11. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  12. PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  13. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  14. PLACEBO DE COLCHICINE 1 mg, COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.

    phase 3 small molecule active

    1 trial

  15. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  16. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  17. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  18. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  19. PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

    Lacuna Pharma Pty Ltd

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  20. PREDNISONE, PREDNISONE , HYDROXYCHLOROQUINE

    Pari Pharma GmbH

    Sarcoidosis

    phase 3 small molecule active

    1 trial

  21. PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant cell arteritis (GCA)

    phase 3 small molecule active

    1 trial

  22. PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR

    Pari Pharma GmbH

    CytoMegaloVirus infections, Kidney transplant

    phase 3 small molecule active

    1 trial

  23. PRISTINAMYCIN , AMOXICILLIN , CEFTRIAXONE , LEVOFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFOTAXIME PANPHARMA 1 g, poudre pour solution injectable (IM-IV), -

    Pari Pharma GmbH

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  24. PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule

    Pari Pharma GmbH

    Antisynthetase syndrome-related interstitial lung disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources